How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
In the past, the majority of drugs evaluated in the clinical pharmacology space were small molecules. Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies.
110 
Let's personalize your content